What is the Purpose of this Study?
Primary Objective: - To characterize the safety and tolerability of KST-6051 and to estimate the RDE(s) in participants with advanced or metastatic solid tumors with a KRAS mutation Secondary Objectives: - To evaluate the PK of KST-6051 after administration as an oral tablet formulation - To evaluate preliminary activity of KST-6051 in participants with advanced or metastatic solid tumors with a KRAS mutation
Eligibility
- 1. Age ≥ 18 years.
- 2. Willing and able to give written informed consent.
- 3. Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor.
- 4. Documentation of KRAS mutation prior to the first dose of trial drug(s).
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center : Abrahm Levi
More about this Clinical Trial
What is the full name of this clinical trial?
KST-6051: A First-in-Human Phase 1 Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation